

HEPATOPANCREATOBILIARY CANCER PROGRAM OVERVIEW

We provide the people we care for with:

- the latest minimally invasive, image-guided techniques for diagnosis and treatment
- the benefit of seeing three or four specialists on one day, in one location
- an individualized treatment plan
- a comprehensive risk assessment and long-term surveillance program
- access to innovative clinical trials of chemotherapies, surgical techniques, and advanced technologies that are not available at other hospitals
- genomic sequencing to look for actionable mutations
- non opioid analgesic options for postoperative pain relief

LOCATIONS

Many of our specialists are centrally located at our **Manhattan location**. We also have regional outpatient locations at:

- MSK Basking Ridge, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York

REFER A PATIENT

Contact our [Physician Access Service](#) directly at

800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

Our Team Leaders

William Jarnagin, MD, FACS
Chief, Hepatopancreatobiliary Service;
Leslie Blumgart Chair in Surgery

Mark Schattner, MD, FASGE, AGAF
Chief, Gastroenterology, Hepatology and
Nutrition Service

Michael D'Angelica, MD, FACS
Enid A. Haupt Chair in Surgery;
Director, Hepatopancreatobiliary Fellowship
Program; Director, Surgical Oncology
Fellowship Program

Jeffery Drebin, MD, PhD
Chair, Department of Surgery

Christopher Crane, MD
Vice Chair, Department of Radiation Oncology

T. Peter Kingham, MD, FACS
Director, Global Cancer Disparity Initiatives

Eileen O'Reilly, MD
Associate Director for Clinical Research,
David M. Rubenstein Center for Pancreatic
Cancer Research

Ghassan Abou-Alfa, MD
Medical Oncologist

Karen Brown, MD, FSIR
Interventional Radiologist

Sign up for **OncoNotes**, MSK's clinical updates newsletter.

Go to [MSKCC.org](#), click on the **For Health Professionals** section, and choose "Sign up for Our E-newsletter."



Memorial Sloan Kettering
Cancer Center



Hepatopancreatobiliary Cancer Program



Memorial Sloan Kettering
Cancer Center



Advanced Technologies

- We use the latest laparoscopic and image-guided, robotic surgical techniques, resulting in **greater precision, fewer complications, decreased postoperative pain, shorter hospital stays, and faster recovery** times compared with open surgery.
- We utilize **virtual surgical planning and prognostic imaging markers** to make diagnoses and determine treatment responses.
- We developed **advanced radiotherapy techniques** with ablative doses for longer-term local tumor control and survival rates in people with inoperable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- Our **24-7 pathology lab** processes digitized images of tissue samples very quickly, including during surgery, to help patients avoid unnecessary procedures.

WHY CHOOSE MSK FOR HEPATOPANCREATOBILIARY CANCER CARE?

Expertise

- Our **hepatopancreatobiliary cancer experts** treat liver, gallbladder, bile duct, pancreatic, and gastroneuroendocrine cancers.
- We routinely use **MSK-IMPACT™, a genome-sequencing test** developed at MSK that allows us to quickly determine if tumors have mutations that are actionable with available targeted therapies or if patients may benefit from clinical trials.
- We pioneered the **hepatic parenchymal preservation surgical approach**, which has significantly decreased morbidity and mortality rates after partial hepatectomy.

Leadership

- We **diagnose and treat more people with liver, pancreatic, and bile duct cancer** than any other cancer center in the United States.
- Our surgeons are **global leaders in minimally invasive surgical techniques**.
- Over the past 25 years, we have pioneered liver-directed hepatic arterial infusion (HAI) chemotherapy for people with colorectal liver metastases. Our experts recently published results showing that **adding HAI extends survival significantly, by almost two years**, compared with standard chemotherapy alone.
- We have **more than 25 hepatobiliary clinical trials underway** for a broad range of targeted therapies, emerging immunotherapies, and novel surgical approaches.

By the Numbers

1,000

Hepatopancreatobiliary patient visits per year

4 locations

8

gastroenterologists



200+
Disease Management Team members

17

medical oncologists